Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYK-224 in Heart Failure with Preserved Ejection Fraction (HFpEF)
2023-505919-21-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing BMS-986435/MYK-224 with Placebo (2 arms). Primary endpoint: Number of side effects (adverse events) within the study. Started Apr 2024; status: completed.
02
Drugs
BMS-986435
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2023-505919-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505919-21-00.